PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.
Name:
s00280-018-3532-9.pdf
Size:
988.1Kb
Format:
PDF
Description:
Full text, Open Access article
Affiliation
Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UKIssue Date
2018-04
Metadata
Show full item recordAbstract
Poly(ADP-ribose) polymerase inhibitors (PARPi) have changed the management of high-grade serous ovarian cancer (HGSOC). The rationale for the development of PARPi was based on the concept of synthetic lethality, in which a cell can survive a deficiency of one gene/gene product, but may die if there is a deficiency in a combination of genes/gene products. In women with BRCA1/2 deficiency within their ovarian cancer tissue, inhibition of PARP imposes an intolerable burden of DNA damage repair deficiency and may induce cell death.Citation
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer. 2018, 81(4): 647-658 Cancer Chemother PharmacolJournal
Cancer Chemotherapy and PharmacologyDOI
10.1007/s00280-018-3532-9PubMed ID
29464354Type
ArticleLanguage
enISSN
1432-0843ae974a485f413a2113503eed53cd6c53
10.1007/s00280-018-3532-9
Scopus Count
Collections
Related articles
- Sequential Targeting of PLK1 and PARP1 Reverses the Resistance to PARP Inhibitors and Enhances Platin-Based Chemotherapy in BRCA-Deficient High-Grade Serous Ovarian Cancer with KRAS Amplification.
- Authors: Gasimli K, Raab M, Tahmasbi Rad M, Kurunci-Csacsko E, Becker S, Strebhardt K, Sanhaji M
- Issue date: 2022 Sep 17
- Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.
- Authors: Papa A, Caruso D, Strudel M, Tomao S, Tomao F
- Issue date: 2016 Sep 15
- Real-world Study on the Effect of PARPi as Maintenance Therapy on Platinum Sensitivity after First- and Second-line Chemotherapy in Patients with Recurrent High-grade Serous Epithelial Ovarian Cancer.
- Authors: Guo Y, Chen X, Tang X, Pan S, Zhu T, Zhang Y
- Issue date: 2024
- Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
- Authors: Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Rowe P, Lowe E, Hodgson D, Sovak MA, Matulonis U
- Issue date: 2016 Nov
- Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
- Authors: Ivy SP, Liu JF, Lee JM, Matulonis UA, Kohn EC
- Issue date: 2016